Effect of Recombinant Human Interleukin-11 Combined with Shengxuebao Mixture in the Treatment of Drug-induced Thrombocytopenia of Breast Cancer
Objective:To investigate the effect of Recombinant Human Interleukin-11 combined with Shengxuebao Mixture in the treatment of drug-induced thrombocytopenia of breast cancer.Method:A total of 60 patients with breast cancer admitted to Ganzhou Cancer Hospital from October 2021 to October 2023 were selected and divided into control group and observation group by random number table method,with 30 cases in each group.The patients in both groups were treated with Trastuzumab Emtansine,the control group was given Recombinant Human Interleukin-11,and the observation group was given Recombinant Human Interleukin-11 combined with Shengxuebao Mixture.The clinical efficacy,TCM symptoms,platelet-related indexes and therapeutic safety of the two groups were compared.Result:The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).After treatment,the scores of TCM symptoms in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the platelet-related indexes in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of Recombinant Human Interleukin-11 and Shengxuebao Mixture has a good effect in the treatment of drug-induced thrombocytopenia of breast cancer,which can improve TCM symptoms of patients,improve the level of platelet count and have good treatment safety.
Breast cancerTrastuzumab EmtansineThrombocytopeniaRecombinant Human Interleukin-11Shengxuebao Mixture
万方数据
维普
